Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta

SocGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca. Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta. It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently...
AstraZeneca: SocGen says 'sell' after predicting less than brilliant outlook for Brilinta

SoGen has repeated its ‘sell’ recommendation and £26.75 share price target for pharma giant AstraZeneca (LON:AZN).

Its negativity is based around what it expects to be the less-than-brilliant performance of heart and stroke drug Brilinta.

It predicts other new products such as Onglyza and Bydureon (both for diabetes) will sell at a faster pace than most analysts are currently projecting.

However, it sees challenges for Brilinta: “Our forecasts for sales are significantly below consensus because we see multiple hurdles to its use in the US, such as the negative US data from the PLATO study, which deters doctors from prescribing it, an unhelpful twice daily dosing regimen, and an interaction with statins (which is absent in competitors clopidogrel and Effient).”

At midday the shares were changing hands for £30.67, down 9.5p on the day.

 



Register here to be notified of future AZN Company articles

Timeline

Related Articles

July 20
Horizon has tied up a string of acquisitions and partnerships since it floated on AIM.
April 13

Securing this approval has taken longer than expected, but today's announcement represents a major advance, as indicated by the sharp rise in the share price.


June 25
Allergy Therapeutics has renewed momentum - as its announcement this morning showing a kick-start to its US growth ambitions aptly demonstrated.

© Proactive Investors 2015